OSUR - OraSure Technologies, Inc.
After hours:
| Previous close | 5.0500 |
| Open | 4.9500 |
| Bid | 4.8000 x 1300 |
| Ask | 4.8800 x 1000 |
| Day's range | 4.8590 - 5.0100 |
| 52-week range | 2.6200 - 7.8200 |
| Volume | |
| Avg. volume | 591,337 |
| Market cap | 357.521M |
| Beta (5Y monthly) | 0.08 |
| PE ratio (TTM) | 12.51 |
| EPS (TTM) | 0.3900 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.94 |
Simply Wall St.Time To Worry? Analysts Just Downgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Outlook
Today is shaping up negative for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders, with the analysts delivering...
- Simply Wall St.
Can Mixed Fundamentals Have A Negative Impact on OraSure Technologies, Inc. (NASDAQ:OSUR) Current Share Price Momentum?
Most readers would already be aware that OraSure Technologies' (NASDAQ:OSUR) stock increased significantly by 48% over...
ZacksOraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates
OraSure (OSUR) delivered earnings and revenue surprises of 131.25% and 21.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireOraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth
InteliSwab® test revenue of $118.3 million in Q1, up 33% sequentially; Company delivers cost savings and begins to taper InteliSwab® test production and expenses Gross margins increase 200 basis points sequentially despite mix/pricing headwinds Signs three new molecular partnerships supporting cancer diagnostics, women’s health testing, and microbiome services Q1 GAAP EPS of $0.37; Non-GAAP EPS of $0.47 Improved cash position with $112.4 million in cash and cash equivalents; Company anticipates
- GlobeNewswire
2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET
BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, May 10, 2023. May 10, 2023 schedule: 4:05 p.m. ET – 2023 first quarter financial results press release will be distributed. Prior to the call - To participate in the teleconference, go to the following link to register and the telec
ZacksIs OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year?
Here is how OraSure Technologies (OSUR) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
ZacksOraSure (OSUR) Stock Jumps 9.3%: Will It Continue to Soar?
OraSure (OSUR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
We're Hopeful That OraSure Technologies (NASDAQ:OSUR) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
ZacksZacks.com featured highlights include OraSure Technologies, Compania de Minas Buenaventura SAA and Vipshop
OraSure Technologies, Compania de Minas Buenaventura SAA and Vipshop are part of the Zacks Screen of the Week article.
Zacks3 Low-Beta Stocks to Buy to Combat the Volatile Market
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. OraSure Technologies (OSUR), Compa??ia de Minas (BVN) and Vipshop Holdings (VIPS) are poised to gain.
- Simply Wall St.
OraSure Technologies, Inc. (NASDAQ:OSUR) is a favorite amongst institutional investors who own 79%
Key Insights Institutions' substantial holdings in OraSure Technologies implies that they have significant influence...
ZacksSurging Earnings Estimates Signal Upside for OraSure (OSUR) Stock
OraSure (OSUR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- Simply Wall St.
OraSure Technologies Full Year 2022 Earnings: Beats Expectations
OraSure Technologies ( NASDAQ:OSUR ) Full Year 2022 Results Key Financial Results Revenue: US$387.5m (up 66% from FY...
Motley FoolWhy OraSure Technologies Stock Is Jumping Today
Shares of OraSure Technologies (NASDAQ: OSUR), a medical devices company that makes diagnostic testing kits, were jumping 12.5% higher as of 3:28 p.m. ET on Wednesday. OraSure announced net revenue in the fourth quarter of $123.1 million, up 94% year over year. The company recorded earnings of nearly $15.6 million, or $0.21 per share, based on generally accepted accounting principles (GAAP).
ZacksOraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability
InteliSwab® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab® revenue Signs a deal with Quest Diagnostics Genomic Sequencing Services for saliva collection kits Q4 GAAP EPS of $0.21; Non-GAAP EPS of $0.36 Announces restructuring expected to result in operating expense savings of $15 million to be fully implemented by June 2023; targets achieving cash flow breakeven for core business by end of 2024 Cash balance grows t
- GlobeNewswire
2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET
BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023. February 14, 2023 schedule: 4:05 p.m. ET – 2022 fourth quarter financial results press release will be distributed. Prior to the call - To participate in the teleconference, go to the following link to register and th
- Simply Wall St.
Quite a few insiders invested in OraSure Technologies, Inc. (NASDAQ:OSUR) last year which is positive news for shareholders
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- Simply Wall St.
Investors in OraSure Technologies (NASDAQ:OSUR) have unfortunately lost 74% over the last five years
It is doubtless a positive to see that the OraSure Technologies, Inc. ( NASDAQ:OSUR ) share price has gained some 37...
- GlobeNewswire
OraSure Technologies Continues its Dedication to Ending the HIV Epidemic
Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS DayBETHLEHEM, Pa., Dec. 01, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in the fight against HIV, will ring the closing bell for the Nasdaq Stock Market this afternoon in honor of World AIDS Day. World AIDS Day is commemorated annually on December 1 to raise awareness of the AIDS epidemic and to mourn the loss of those who have died of the disease. The U.S. Government's theme
- GlobeNewswire
OraSure Technologies to Present at Stephens Annual Investment Conference
BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Ken McGrath, Chief Financial Officer, will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022 at 9:00 am ET. The conference will be simultaneously webcast over the Internet. Live webcasts and replays of the presentations
ZacksOraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates
OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year
InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially;Company continues to expand test production capacity Company wins new contracts for COVID-19 testing along with retail wins including availability on Amazon.com Q3 GAAP EPS of $0.07 and non-GAAP EPS of $0.13 Company generates positive cash flow from operations in quarter ahead of prior guidance Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- OraSure Technol
- GlobeNewswire
OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)
FDA Clearance Received Through Partnership with Grifols to Support Screening for Risk of Alpha1- Antripsyn Deficiency (Alpha-1) in U.S. Adult Population BETHLEHEM, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Company received U.S. FDA clearance for its ORAcollect®•Dx saliva collection device for OTC (i.e. direct-to-consumer) use. The devic
- GlobeNewswire
InteliSwab® COVID-19 Rapid Test Now Available in Amazon’s Online Store
BETHLEHEM, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab® COVID-19 Rapid Test is now available in Amazon’s online store to customers in the United States. The product will be sold and fulfilled by Amazon and eligible for free Amazon Prime shipping. “Amazon has strong consumer reach in the United States, which will help facilitate